POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the major intracellular cation; it maintains intracellular tonicity, transmembrane potential, and normal neuromuscular excitability. Chloride is the major extracellular anion; together with sodium, it maintains extracellular tonicity and acid-base balance.
| Metabolism | Potassium is not metabolized; it is eliminated primarily by the kidneys, with small amounts excreted in feces and sweat. Chloride is also mainly excreted by the kidneys. |
| Excretion | Renal: >90% excreted unchanged in urine; minor fecal elimination (<2%) via biliary route. |
| Half-life | Terminal elimination half-life: 10–20 minutes in healthy individuals; context: reflects rapid renal clearance; prolonged in renal impairment or reduced glomerular filtration rate. |
| Protein binding | Approximately 10% bound to albumin; minimal binding to other plasma proteins. |
| Volume of Distribution | 0.1–0.2 L/kg; clinical meaning: reflects primary distribution in extracellular fluid; larger Vd in hypokalemia due to cellular uptake. |
| Bioavailability | Intravenous: 100%; oral (not applicable here): not relevant for this formulation. |
| Onset of Action | Intravenous: Immediate (within seconds to minutes) due to direct vascular access. |
| Duration of Action | Intravenous: Duration of effect is dependent on continuous infusion; bolus effects may last minutes; context: rapid redistribution and excretion necessitate continuous administration for sustained replacement. |
40 mEq potassium chloride in 0.9% sodium chloride intravenously at a maximum rate of 10 mEq/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: reduce dose by 25-50%. GFR <10 mL/min: reduce dose by 50% or use with caution. |
| Liver impairment | No specific adjustment for Child-Pugh class. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances. |
| Pediatric use | 0.5-1 mEq/kg/dose intravenously, maximum 40 mEq/dose. Infuse at ≤0.5 mEq/kg/hour. |
| Geriatric use | Start at lower end of dosing range (e.g., 20 mEq) and titrate slowly due to decreased renal function. Maximum infusion rate 10 mEq/hour. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium is a normal component of breast milk and is actively secreted; levels in milk parallel maternal serum concentrations. M/P ratio approximately 1.0. Supplementation at usual doses is considered compatible with breastfeeding. |
| Teratogenic Risk | Potassium chloride is an essential electrolyte; no teratogenic effects have been reported at normal physiological levels. In first trimester: no known risk. Second trimester: no known risk. Third trimester: no known risk. High doses may cause maternal hyperkalemia, which can lead to fetal arrhythmias or death. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (≥ 2 mEq/mL) must be diluted before administration. Rapid infusion or high concentration can cause fatal cardiac arrhythmias due to hyperkalemia.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia (serum potassium > 5.5 mEq/L)","Severe renal impairment with oliguria or anuria","Untreated Addison's disease","Acute dehydration, heat cramps, or severe tissue breakdown (e.g., severe burns)","Concomitant use of potassium-sparing diuretics or ACE inhibitors without close monitoring"]
| Precautions | ["Monitor serum potassium levels closely during therapy","Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Avoid rapid infusion or high concentrations which can cause cardiac arrest","Do not use in patients with untreated Addison's disease, acute dehydration, heat cramps, or severe renal impairment","Administration may cause local phlebitis and extravasation"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, electrolytes, renal function, and ECG periodically. Assess for signs of hyperkalemia (muscle weakness, cardiac arrhythmias). Fetal heart rate monitoring may be indicated if maternal electrolyte disturbances occur. |
| Fertility Effects | No known adverse effects on fertility. Potassium is essential for normal cellular function, and maintaining normokalemia is important for reproductive health. |